Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Nat Med. 2013 Aug 18;19(9):1132–1140. doi: 10.1038/nm.3265

Figure 1.

Figure 1

Effects of peripheral CB1R blockade on body weight, adiposity, hepatic lipogenesis and glycemic control in ZDF rats. Eight-week-old male ZDF rats treated for 28 d by oral gavage with 3 mg per kg body weight per day JD5037 or vehicle, (a) Effects of vehicle (gray columns and squares) and JD5037 (black columns and triangles) treatment of ZDF rats on body weight, adiposity and food intake compared to lean controls (white columns and open circles), n-20 pergroup. (b–d) Effects of vehicle (gray) and JD5037 (black) treatment of the same ZDF rats compared to lean controls (white) on hepatic triglycerides (FG), plasma alanine aminotransferase (ALT) and hepatic Fas and Scd1 (b; n = 20 per group); on fasting blood glucose, HbA1c plasma insulin and C-peptide levels (c; n = 20 per group), and on the glucose-infusion rate (GIR), the percentage of suppression of hepatic glucose production (HGP) and the rate of glucose disappearance (Rd) during a euglycemic-hyperinsuiinemic clamp (d; n = 5 per group). Data are expressed as means means ± s.e.m. from 20 rats pergroup; * P < 0.05, ** P < 0.01, *** p < 0.001.